It’s a matter of days

EVERY DAY YOUR PATIENT TAKES OPIOIDS

their risk of forming a deadly addiction increases

Dependency can begin within 3 days of opioid use1

You have the power to defuse the opioid crisis and there are choices…

With over 20 years of innovation and over 100 clinical studies, ON-Q* gives you and your patients peace of mind, with proven opioid-sparing pain control for up to 5 days.

Choosing liposomal bupivacaine (LB) however could mean the following risks:

  • For breakthrough pain, additional local anesthetics cannot be used for up to 96 hours after administration due to potential risk of local anesthetic toxicity (LAST)2,3 †
  • It’s UNKNOWN if intralipid rescue will provide emergency rescue of LB in the event of LAST4
  • INABILITY to turn off or control if complications arise, eg diaphragmatic paralysis 4
ON-Q* provides:
CUSTOMIZABLE PAIN CONTROL
ON-Q* provides:
PAIN CONTROL FOR DAYS
ON-Q* provides:
REDUCED NEED FOR OPIOIDS

1. Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use – United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):265-269.
2. EXPAREL PI. Accessed 2018 Apr 16.
3.Noviasky J, Pierce D, Whalen K, Guharoy R, Hildreth K. Bupivacaine Liposomal Versus Bupivacaine: Comparative Review. Hosp Pharm. 2014 Jun; 49(6): 539–543.
Bernardo M, Cao N, Moazeni S, Buljubasic A, Buljubasic A, Rahman S et al. Abstract 21365: Intralipid fails to rescue liposomal bupivacaine (Exparel)-induced cardiac arrest in rats. Circulation 2017;136:A21365.
5. Neal JM, Gerancher JC, Hebl JR, Ilfeld BM, McCartney CJ, Franco CD, et al. Upper extremity regional anesthesia: essentials of our current understanding, 2008. Reg Anesth Pain Med. 2009;34(2):134–170. doi:10.1097/AAP.0b013e31819624eb.
6. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. Sep 2011;28(9):776-788.
7. Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. Sep 2011;28(9):776-788.
8. Vandepitte C, Kuroda M, Witvrouw R, Anne L, Bellemans J, Corten K. et al. Addition of liposome Bupivacaine to bupivacaine HCl versus bupivacaine HCl alone for interscalene brachial plexus block in patients having major shoulder surgery. Reg Anesth Pain Med. 2017;42(3):334-341. doi: 10.1097/AAP.0000000000000560.
9. Hadzic A, Minkowitz H, Melson TI, Berkowitz R, Uskova A, Ringold F, et al. Liposome bupivacaine femoral nerve block for postsurgical analgesia after total knee arthroplasty. Anesthesiology. 2016;124(6):1372-83. doi: 10.1097/ALN.0000000000001117.
10. Abildgaard JT, Lonergan KT, Tolan SJ, Kissenberth MJ, Hawkins RJ, Washburn R 3rd, et al. Liposomal bupivacaine versus indwelling interscalene nerve block for postoperative pain control in shoulder arthroplasty: a prospective randomized controlled trial. J Shoulder Elbow Surg. 2017;26(7):1175-1181. doi: 10.1016/j.jse.2017.03.012.
11. Namdari S, Nicholson T, Abboud J, Lazarus M, Steinberg D, Williams G. Randomized controlled trial of interscalene block compared with injectable liposomal bupivacaine in shoulder arthroplasty. J Bone Joint Surg Am. 2017;99(7):550-556. doi: 10.2106/JBJS.16.00296.

ON-Q* TRAC is not a medical device.

There are inherent risks in all medical devices, please refer to the product labeling for Indications, Cautions, Warnings and Contraindications. For example, failure to follow the product labeling regarding filling, flow rate selection and placement of the pump and/or catheter could directly impact patient safety. Physician is responsible for prescribing and administering medications per instructions provided by the drug manufacturer. Refer to the website for product safety Technical Bulletins. For specific questions regarding the pump or medication prescribed to you, please contact your physician.